Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by University of Colorado, Boulder
Sponsor:
Collaborator:
Forest Laboratories
Information provided by (Responsible Party):
Christopher DeSouza, University of Colorado, Boulder
ClinicalTrials.gov Identifier:
NCT01595516
First received: March 5, 2012
Last updated: December 2, 2014
Last verified: December 2014
History of Changes
  Purpose

The investigators hypothesize that nebivolol will improve endothelial t-PA release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. The investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-PA with nebivolol is mediated, in part, by the compound's antioxidant properties.


Condition Intervention Phase
Prehypertension
Hypertension
 Drug: Nebivolol
Drug: Metoprolol
Drug: Placebo
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Official Title: Nebivolol and Endothelial Regulation of Fibrinolysis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Colorado, Boulder:

Primary Outcome Measures:
  • Changes from baseline in endothelial t-PA release [ Time Frame: t-PA release will be measured at week 3 (before the 12 week drug or placebo intervention) and at week 15 (after the 12 week drug or placebo intervention). ] [ Designated as safety issue: No ]
    t-PA release is measured in response the bradykinin, sodium nitroprusside, vitamin C and bradykinin+vitamin C
Estimated Enrollment: 54
Study Start Date: February 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nebivolol Drug: Nebivolol
5 mg tablet to be taken by mouth once per day for 12 weeks
Other Name: Bystolic
Active Comparator: Metoprolol Drug: Metoprolol
100 mg tablet to be taken by mouth once per day for 12 weeks
Other Name: Toprol-XL
Placebo Comparator: Placebo Drug: Placebo
Gelatin capsule to be taken by mouth once per day for 12 weeks

  Eligibility
Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.
  • Subjects will be prehypertensive/hypertensive defined as resting systolic blood pressure >125 mmHg and <160 mmHg and/or diastolic >80 mmHg and <100 mmHg.
  • All of the women in the study will be postmenopausal and not receiving hormone replacement therapy (HRT) currently or in the preceding 3-year period.
  • Candidates will be sedentary as determined from the Stanford Physical Activity Questionnaire (<35 kcal/wk) and will not have engaged in any program of regular physical activity for at least 1 year prior to the study.

Exclusion Criteria:

  • Candidates who smoke (currently or in the past 7 years), report more than low-risk alcohol consumption as defined as no more than 14 standard drinks/wk and no more than 4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1½ ounces of 80-proof distilled spirits).
  • Potential candidates who are taking cardiovascular-acting (i.e. statins, blood pressure medication and aspirin) medications will not be eligible.
  • Fasting plasma glucose >126 mg/dL.
  • Potential candidates with a resting heart rate of < 50 beats/minute will be excluded.
  • Use of hormone replacement therapy.
  • In hypertensive subjects, a seated systolic blood pressure >160 mmHg or a seated diastolic blood pressure >100 mmHg will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01595516

Contacts
Contact: Jared Greiner, M.S. 303-735-4955 jared.greiner@colorado.edu

Locations
United States, Colorado
UC-Boulder Clinical and Translational Research Center Recruiting
Boulder, Colorado, United States, 80309
Contact    303-735-3056      
Principal Investigator: Christopher DeSouza, Ph.D.         
Sponsors and Collaborators
University of Colorado, Boulder
Forest Laboratories
Investigators
Principal Investigator: Christopher DeSouza, Ph.D. University of Colorado at Boulder
  More Information

No publications provided

Responsible Party: Christopher DeSouza, Professor, University of Colorado, Boulder
ClinicalTrials.gov Identifier: NCT01595516     History of Changes
Other Study ID Numbers: BYS-MD-72
Study First Received: March 5, 2012
Last Updated: December 2, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Nebivolol
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Antihypertensive Agents
Cardiovascular Agents
 Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents

ClinicalTrials.gov processed this record on February 27, 2015